The purpose of this study is to investigate if Quercetin Phytosome is beneficial for the treatment of COVID-19.
This is a randomized, open-labelled and controlled study aimed to investigate the adjuvant
benefits of Quercetin Phytosome in community-based subjects with confirmed SARS-CoV-2
infection (by RT-PCR). The study has two arms. In one arm the subjects will receive standard
COVID-19 care as per the hospital/physician guidelines, whereas in the other arm the subjects
will receive standard COVID-19 care + Quercetin Phytosome. The treatment will continue for 30
days. It is proposed that Quercetin Phytosome will contribute to boosting the natural
immunity of the subjects and will help in preventing the COVID-19 disease progression i.e
preventing the need of hospitalisation.
Drug: Standard COVID-19 care
Patients will receive standard covid-19 care as per the hospital/physician guidelines
Dietary Supplement: Quercetin Phytosome
Patients will receive a daily dose of 400 mg of oral Quercetin Phytosome
Inclusion Criteria:
- Age ≥ 18 years of either gender
- Confirmed SARS-CoV-2 infection by RT-PCR
- Currently diagnosed with mild-to-moderate symptoms of COVID-19 at home in
self-isolation within 3 days of SARS-CoV-2 infection.
- Displaying typical symptoms of COVID-19 such as a high temperature, a new, continuous
cough, a loss or change to sense of smell or taste
- Patients who have signed informed consent.
Exclusion Criteria:
- Patients with proven hypersensitivity or allergic reaction to quercetin
- Manifest contrary will
Liaquat University Hospital
Jāmshoro, Sindh, Pakistan